WO2015014284A1 - Méthode de traitement du cancer du sein - Google Patents

Méthode de traitement du cancer du sein Download PDF

Info

Publication number
WO2015014284A1
WO2015014284A1 PCT/CN2014/083287 CN2014083287W WO2015014284A1 WO 2015014284 A1 WO2015014284 A1 WO 2015014284A1 CN 2014083287 W CN2014083287 W CN 2014083287W WO 2015014284 A1 WO2015014284 A1 WO 2015014284A1
Authority
WO
WIPO (PCT)
Prior art keywords
score
staining
cell membrane
breast cancer
cytoplasmic
Prior art date
Application number
PCT/CN2014/083287
Other languages
English (en)
Chinese (zh)
Inventor
孟坤
陈凤
王兆一
白伟
王培培
王伟娜
Original Assignee
北京盛诺基医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京盛诺基医药科技有限公司 filed Critical 北京盛诺基医药科技有限公司
Publication of WO2015014284A1 publication Critical patent/WO2015014284A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de traitement du cancer du sein. Ladite méthode consiste d'abord à vérifier l'expression d'ER-α36 dans le tissu de l'échantillon tumoral d'un patient atteint de cancer du sein par immunohistochimie, et à administrer au patient un inhibiteur de l'enzyme aromatase si l'expression d'ER-α36 est élevée.
PCT/CN2014/083287 2013-07-31 2014-07-30 Méthode de traitement du cancer du sein WO2015014284A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310326504.8 2013-07-31
CN201310326504 2013-07-31

Publications (1)

Publication Number Publication Date
WO2015014284A1 true WO2015014284A1 (fr) 2015-02-05

Family

ID=52431007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/083287 WO2015014284A1 (fr) 2013-07-31 2014-07-30 Méthode de traitement du cancer du sein

Country Status (1)

Country Link
WO (1) WO2015014284A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2976362A4 (fr) * 2013-03-19 2017-03-22 Beijing Shenogen Pharma Group Ltd. Anticorps et procédés permettant de traiter des maladies associées aux récepteurs des strogènes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1756549A (zh) * 2003-03-05 2006-04-05 惠氏公司 包含雷帕霉素衍生物和芳化酶抑制剂的抗肿瘤组合
CN102558164A (zh) * 2010-12-31 2012-07-11 北京盛诺基医药科技有限公司 苯并吡喃酮类雌激素受体调节剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1756549A (zh) * 2003-03-05 2006-04-05 惠氏公司 包含雷帕霉素衍生物和芳化酶抑制剂的抗肿瘤组合
CN102558164A (zh) * 2010-12-31 2012-07-11 北京盛诺基医药科技有限公司 苯并吡喃酮类雌激素受体调节剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2976362A4 (fr) * 2013-03-19 2017-03-22 Beijing Shenogen Pharma Group Ltd. Anticorps et procédés permettant de traiter des maladies associées aux récepteurs des strogènes
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases

Similar Documents

Publication Publication Date Title
Woolard et al. Molecular diversity of VEGF-A as a regulator of its biological activity
Zhao et al. Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts
Leong et al. Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels
CN107532217A (zh) 用于癌症的治疗和诊断方法
Yang et al. Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system
WO2021128516A1 (fr) Application de circrna pvt1 et de peptide dans la prédiction de la croissance tumorale, la prédiction de métastases, l'évaluation pronostique et le traitement
Montecinos et al. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma
WO2018133635A1 (fr) Modèle de xénogreffe de poisson zèbre à cellules tumorales, et procédé de construction et d'application associé
WO2014082085A1 (fr) Utilisation d'inhibiteurs d'itk pour le traitement du cancer
Schmidt et al. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage
CN110302382A (zh) 一种靶向肿瘤细胞的药物
JP6810609B2 (ja) Ｅｈｄ２抗体とその乳がん免疫組織化学的検出試薬の製造への応用
WO2019233469A1 (fr) Utilisation d'un inhibiteur de la voie de signalisation pdgfr pour la préparation d'un médicament destiné au traitement de maladies inflammatoires intestinales
Liu et al. Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy
Othman et al. Immunohistochemical expression of MAP1LC3A and MAP1LC3B protein in breast carcinoma tissues
Horiguchi et al. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer
WO2015014284A1 (fr) Méthode de traitement du cancer du sein
AU2016352592A1 (en) Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
Wu et al. Potassium channel ether a go-go1 is aberrantly expressed in human liposarcoma and promotes tumorigenesis
CN105420194B (zh) mPRα介导孕酮调节肺腺癌细胞对EGFR-TKIs敏感性的方法
TW201538162A (zh) 微小ＲＮＡ ｍｉＲ－１９９ａ－５ｐ之用途
Prakash et al. A study of luteal phase expression of inhibin, activin, and follistatin subunits in the endometrium of women with recurrent miscarriage
WO2015010596A1 (fr) Procédé de diagnostic pronostique du cancer du sein
WO2016206596A1 (fr) Application de cthrc1 dans le diagnostic et le traitement de la cirrhose du foie
Susarla et al. Expression of receptors for VEGFs on normal human thyroid follicular cells and their role in follicle formation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832649

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/05/2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14832649

Country of ref document: EP

Kind code of ref document: A1